Webcast

Noxopharm Investor Briefing – 8 July

July 8, 2020

Noxopharm Investor Briefing – 8 July

Noxopharm (ASX: NOX) Webcast Replay

Noxopharm (ASX: NXO) is an Australian-based, clinical stage drug development company which focuses on two areas of drug technology.

As a part of our ‘Meet the CEOs’ series, CEO Graham provides valuable insights to the company, its key markets and industry, and future prospects.

Recorded on 8th July 2020 at 12pm (AEST).

Join the next Meet the CEOs webcast

Speak to our Advisor team about this company

FEATURE SPEAKERS

Graham Kelly

Chairman & CEO

Noxopharm (ASX: NXO) is an Australian-based, clinical stage drug development company which focuses on two areas of drug technology. The first is the potential benefit to cancer patients in being able to increase their responsiveness to standard of care chemotherapies and radiotherapies. Veyonda is the first pipeline drug candidate, with later generation drug candidates under investigation in an R&D program. The second area relates to the technology behind Veyonda and the opportunity it offers to exploit the broader therapeutic opportunities of isoflavonoid compounds.

Speak to our Advisor team about this company



By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.